Amgen to bring Adaptive's MRD diagnostic to its wider blood cancer portfolio

Red blood cells
Adaptive Biotechnologies' clonoSEQ received de novo clearance last year for monitoring minimal residual disease in multiple myeloma and B-cell acute lymphoblastic leukemia. (Pixabay)

For multiple development programs across its global blood cancer portfolio, Amgen has tapped Adaptive Biotechnologies to deliver next-generation sequencing (NGS) assays as it moves drugs toward approval.

Under a four-year agreement, Adaptive’s clonoSEQ Assay will be used to assess minimal residual disease (MRD) in ongoing and future clinical trials. In return, Amgen will pay out annual development fees plus sequencing payments and regulatory milestone awards.

“We are excited to continue working with Amgen as their preferred partner to support the development and regulatory approval of novel blood cancer treatments,” Adaptive co-founder and CEO Chad Robins said in a statement.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

The two companies began working together in 2016 to assess MRD in acute lymphoblastic leukemia. The new deal aims to expand and validate the use of the biomarker as an outcomes measure across multiple cancers.

RELATED: Immune cell-sequencer Adaptive Biotechnologies plans $200M IPO

“This pan-portfolio partnership reflects Amgen’s confidence in the role that standardized NGS MRD testing with clonoSEQ plays in demonstrating drug efficacy in clinical trials and in day-to-day patient management,” Robins said.

As a single-site in vitro diagnostic performed at Adaptive’s lab, clonoSEQ uses multiplex immunosequencing to identify the DNA sequences found in malignant cells and can detect MRD at levels below one in 1 million cells.

RELATED: Microsoft joins Adaptive’s pursuit of blood-based diagnostics

It received a de novo clearance from the FDA last year for monitoring MRD in patients with multiple myeloma and B-cell acute lymphoblastic leukemia using bone marrow samples and is available as a laboratory-developed test for other lymphoid cancers.

"It is critical to know a patient’s MRD status because treating to MRD negativity has been shown to drive better clinical outcomes for patients in a variety of blood cancers," said Gregory Friberg, Amgen’s vice president of global development. “Standardized, highly sensitive, molecular detection of MRD using clonoSEQ supports the development of potential cancer therapies that can help patients with blood cancer live longer.”

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

The supermarket chain received an emergency authorization for its own home collection kit for COVID-19 testing, which includes a telehealth consult.

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.